Uptravi dosing vs Adverse events
Uptravi dosing vs Adverse events
REFERENCES
1. Uptravi Summary of Product Characteristics. Actelion Pharmaceuticals Ltd; 2017. https://www.ema.europa.eu/en/documents/product-information/uptravi-epar-product-information_en.pdf . Accessed September 2020.
2. Sitbon 0, Channick R, Chin KM, et al; for the GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015; 373(26):2522-2533.
CP-266811
